Quote Request
Peptide Drug Development for Pancreatic Cancer
Pancreatic cancer, a highly aggressive and deadly malignant tumor with a poor prognosis. Researchers are studying and developing peptide drugs to target pancreatic cancer. With extensive experience in basic pancreatic cancer research, Alfa Cytology aims to provide researchers around the world with a comprehensive solution for peptide drug development, ensuring reliable results in preclinical studies.
Overview of Peptide Drug Development for Pancreatic Cancer
The challenges of early detection and the highly aggressive nature of pancreatic cancer limit treatment options. Currently, available immunotherapies and targeted therapies have shown limited efficacy and may be associated with significant toxicity or high treatment costs. In addition, the failure of many pancreatic cancer clinical trials further emphasizes the urgent need for breakthroughs in this field. Peptide-based biotherapeutics have become an attractive area of research due to their favorable properties, such as high selectivity and affinity, low immunogenicity, chemical modifiability, good tissue permeability, and easy metabolism and excretion.
Fig. 1 Mechanisms of anti-cancer peptides. (Nhàn NTT, et al, 2023)
Peptide-based Cancer Therapeutics
Therapeutic peptides commonly function as hormones, growth factors, neurotransmitters, ion channel ligands or anti-infective agents. Based on function and mechanism of action, therapeutic peptides mainly include the following two categories.
Anti-Cancer Peptides (ACPs)
ACPs are short bioactive peptides consisting of 10 to 60 amino acids that specifically target proteins involved in cell cycle regulation, growth factor signaling, or survival pathways to inhibit cancer cell growth without affecting normal cells. Common mechanisms of action of anticancer peptides include:
- Induction of Apoptosis
- Membrane Disruption
- Immunomodulation
- Angiogenesis Inhibition
Tumor-Homing Peptides (THP)
THPs are oligopeptides consisting of less than 30 amino acids designed to recognize specific markers such as integrins, growth factor receptors and other cancer-specific antigens and to integrate efficiently into tumor cells. It is used to bind to various therapeutic agents, including cytotoxic drugs, radionuclides, or nanoparticles, which are then delivered to the cancer cells, leading to their destruction.
Our Services
Alfa Cytology is dedicated to the development of peptides with high specificity and efficacy against pancreatic cancer cells, and our comprehensive services include target identification, peptide design and synthesis, characterization, optimization, and comprehensive evaluation, ultimately facilitating the development of innovative therapies.
Peptide Drugs Development Services
- Design high-purity, highly specific and stable peptides for targeted pancreatic cancer therapy by recombinant DNA technology.
- Enable precise and scalable synthesis for a variety of research and therapeutic applications.
- Create peptides coupled to cytotoxic agents, which involves a systematic approach to peptide synthesis, linker technology, and drug conjugation.
- Enhanced precision in targeting PC, increased therapeutic efficacy, and reduced side effects.
Synthetic Peptide
- Develops chemically synthesized peptides with high purity and specificity, tailored for research and therapeutic purposes in pancreatic cancer.
- Customizable synthesis processes that ensure reproducibility, scalability, and enhanced stability.
Why Choose Us?
Customized Peptide Design
We specifically tailor peptide sequences to target specific molecular markers and pathways associated with pancreatic cancer. This tailored approach ensures high specificity and effectiveness.
Integration of Cutting-edge Technologies
Our services integrate cutting-edge technologies such as computational modeling and high-throughput screening to accelerate peptide design and optimization.
Comprehensive Preclinical Evaluation
We conduct comprehensive preclinical evaluations using advanced in vitro and in vivo models to evaluate the efficacy, safety, and pharmacokinetic profile of polypeptide drugs.
Peptide drugs offer a promising approach for targeted pancreatic cancer therapy. Alfa Cytology's team of experienced researchers and scientists work closely with academic institutions and biotechnology partners to foster innovation and accelerate peptide drug candidates from discovery to transformation. For more information and to explore collaboration opportunities, please do not hesitate to contact us.
References
- Nhàn NTT, et al. Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions. International Journal of Molecular Sciences. 2023; 24(16):12931.
- Vadevoo, SMP, et al. Peptides as multifunctional players in cancer therapy. Exp Mol Med 55. 2023, 1099–1109.
